Literature DB >> 28159043

Role of prophylactic antibiotics in lesser toe fusion surgery: A prospective randomised controlled trial.

J Mangwani1, A Gulati2, R Benson3, M Cichero4, D M Williamson5.   

Abstract

BACKGROUND: This prospective randomised controlled trial was performed to determine whether the incidence of local infection is reduced in patients who are administered prophylactic antibiotics for lesser toe fusion surgery.
METHODS: 100 adult patients undergoing toe fusion surgery that required K-wires to be left in situ for 4-6 weeks were randomly allocated into those who received prophylactic antibiotics (Group 1, n=48) and those who did not (Group 2, n=52). Patients were followed up regularly and during each visit K-wire insertion sites were assessed for signs of pin tract infection.
RESULTS: The mean age of Group 1 was 58.0 (SD 17.5) and Group 2 was 62.7 years (SD 14.7). The overall infection rate was 4%. Three patients (6.2%) in Group 1 and one patient (1.9%) in Group 2 developed signs of infection, which required treatment by oral antibiotics. All infections were low grade. There were no features suggestive of osteomyelitis in any of the patients.
CONCLUSION: The overall infection rate in lesser toe fusion surgery is low and that using prophylactic antibiotics does not reduce the incidence. Inappropriate use of antibiotics, however, may contribute to the development of antibiotic resistance and adds to healthcare costs.
Copyright © 2016 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; Infection; K-wires

Mesh:

Year:  2016        PMID: 28159043     DOI: 10.1016/j.fas.2016.02.004

Source DB:  PubMed          Journal:  Foot Ankle Surg        ISSN: 1268-7731            Impact factor:   2.705


  1 in total

1.  Antibiotic prophylaxis in foot and ankle surgery: a systematic review of the literature.

Authors:  Mr Ravi Krishān Modha; Chris Morriss-Roberts; Madeleine Smither; Jonathan Larholt; Ian Reilly
Journal:  J Foot Ankle Res       Date:  2018-11-15       Impact factor: 2.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.